XT-150 is currently in two P2 clinical studies for Osteoarthritis Pain.
TLR4 was recently awarded a $3M USD grant from the Department of Defense.
Xalud Therapeutics, Inc. is developing novel therapies for the treatment of neuro-inflammatory diseases. Xalud is also developing treatments for inflammatory joint disorders including osteoarthritis and rheumatoid arthritis.
Xalud welcomes inquiries regarding development partnerships, investment and scientific collaboration. Please contact us if you are interested in learning more about Xalud. We look forward to speaking with you.